Skip to content

Phenotypic Exploration During Sensory Stimulation in an Acoustic Chamber

Exploration phénotypique en Contexte de Stimulations Sensorielles en Chambre Acoustique

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07544563
Acronym
EMO-INTRA
Enrollment
320
Registered
2026-04-22
Start date
2025-12-02
Completion date
2035-12-02
Last updated
2026-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Depression Anxiety Disorder, Epilepsy

Brief summary

An observational behavioural and neurophysiological study of the effects of controlled sensory stimulation (such as music, for example) on brain function

Interventions

None listed

Sponsors

Centre Hospitalier St Anne
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* For patients : epilepsy * For healthy volunteers: age \> 18 yo

Exclusion criteria

* For patients and healthy volonteers : Deafness * For healthy volunteers : History of neurological conditions (including stroke, coma, epilepsy, neuro-inflammatory or neurodegenerative disease) or diagnosed cognitive impairment

Design outcomes

Primary

MeasureTime frameDescription
Neuronal networksAll along the study (8 years)Description of the neural networks involved during exposure to sensory stimuli

Secondary

MeasureTime frameDescription
Psychologic outcome : anxiety8 yearsAssessment of the Generalized Anxiety Disorder-7 (GAD7) in the exposed patients across the hospitalization : minimum value 0; maximum 21; higher scores mean a worse outcome
Psychologic outcome 2 : depression8 yearsAssessment of the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) in the exposed patients across the hospitalization : minimum value 6; maximum 24; higher scores mean a worse outcome
Quality of life measure8 yearsAssessment of the QOLIE-31(quality of life in epilepsy) scale among exposed patients

Countries

France

Contacts

CONTACTViviane AWASSI
v.awassi@ghu-paris.fr+33145658486

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 23, 2026